BIOTECH HOLDRS TRUST - FORM 8-K - EX-99.1 - PROSPECTUS SUPPLEMENT - May 25, 2011

Attached files

file filename
8-K - CURRENT REPORT - BIOTECH HOLDRS TRUSTss119580_8k-biotech.htm

PROSPECTUS SUPPLEMENT
EXHIBIT 99.1
(To Prospectus dated March 15, 2011)
REGISTRATION NO.  333-89355
 
 
 
 
1,000,000,000 Depositary Receipts
Biotech HOLDRS (SM) Trust

This prospectus supplement supplements information contained in the prospectus dated March 15, 2011 relating to the sale of up to 1,000,000,000 depositary receipts by the Biotech HOLDRS (SM) Trust.
 
The share amounts specified in the table in the “Highlights of Biotech HOLDRS” section of the base prospectus shall be replaced with the following:
 
Name of Company1
  
Ticker
  
Share
Amounts
  
Primary U.S.
Trading Market
Affymetrix, Inc.
  
AFFX
   4.0000  
NASDAQ GS
Alkermes, Inc.
  
ALKS
   4.0000  
NASDAQ GS
Amgen Inc.
  
AMGN
   64.4800  
NASDAQ GS
Biogen Idec Inc.
  
BIIB
   26.9500  
NASDAQ GS
Enzon Pharmaceuticals, Inc.
  
ENZN
   3.0000  
NASDAQ GM
Gilead Sciences, Inc.
  
GILD
   64.0000  
NASDAQ GS
Human Genome Sciences, Inc.
  
HGSI
   8.0000  
NASDAQ GM
Life Technologies Corporation
  
LIFE
   8.1774  
NASDAQ GS
QLT Inc.
  
QLTI
   5.0000  
NASDAQ GS
Shire plc
  
SHPGY
   6.8271  
NASDAQ GS

The share amounts listed in the table above reflect all previous stock splits, dividends and business combination transactions.

The date of this prospectus supplement is May 25, 2011.
 




 
 1 On May 17, 2011, the acquisition of Celera Corporation by Quest Diagnostics Incorporated became effective.  As a result, Celera Corporation will no longer be an underlying constituent of the Biotech HOLDRS Trust.  Quest Diagnostics Incorporated will not be added as an underlying constituent of the Biotech HOLDRS Trust.  In connection with the acquisition, Celera Corporation shareholders will receive $8.00 in cash for each share of Celera Corporation.  The Bank of New York Mellon will receive $32.00 for the 4 shares of Celera Corporation per 100 share round-lot of Biotech HOLDRS.  The Bank of New York Mellon will distribute cash at a rate of $0.32 per depositary share of Biotech HOLDRS. The record date for the distribution is May 31, 2011 and the payable date is to be determined.